Clinical Trials Logo
  1. Home
  2. Schizotypal Personality Disorder
  3. NCT04764708

Compassion and Metacognition in Schizotypal Personality — CMBT  

Schizotypal Personality Disorder Clinical Trial

Official title:
Compassion and Metacognition Based Therapy for Schizotypal Personality Disorder: A Pilot Non-inferiority Randomized Controlled Trial on Repeated Measures.

Clinical Trial Summary

The purpose of this study is to assess the safety and efficacy of a newly developed psychotherapy for schizotypal personality disorder. This new form of psychotherapy integrates compassion focused therapy and metacognitively oriented psychotherapy.

Clinical Trial Description

After being informed about the study and potential risks, all patients giving written informed consent will undergo a psychological assessment so as to determine eligibility for study entry. Patients who meet the eligibility requirements will be randomized in a double-blind manner in a 1:1 ratio to new integrative psychotherapy or treatment as usual (cognitive behavioral therapy plus standard psychopharmacological treatment). One month after the conclusion of the two forms of treatment (both lasting 6 months), patients will have access to the final follow-up assessment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04764708
Study type Interventional
Source Tages Onlus
Contact
Status Completed
Phase N/A
Start date December 15, 2020
Completion date December 20, 2021
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02149823 - Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Phase 1
Terminated NCT00353379 - Pharmacology of Cognition in Schizotypal Personality Disorder Phase 4
Recruiting NCT05710926 - Evolutionary Systems Therapy for Schizotypy N/A
Recruiting NCT00252044 - Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder N/A
Completed NCT00158028 - Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder N/A
Completed NCT02800681 - Psychopathological Differences Between Asperger Syndrome and Schizotypal Disorder in an Adult Sample
Completed NCT02524899 - CRT-Guanfacine for SPD Phase 2
Recruiting NCT01466205 - Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder Phase 2
Completed NCT02535156 - Schizotypal Personality Disorder Risperidone Phase 1/Phase 2
Completed NCT02507206 - A D1 Agonist For Working Memory Phase 2